CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation
Status:
Unknown status
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, single arm, phase II study evaluating efficacy in terms of RR in a
cohort of NSCLC with MET amplification or MET exon 14 skipping mutation pre-treated or not
with MET inhibitors.